Aurora Cannabis Inc experienced a notable surge in its stock price, reflecting positive market sentiment.
Aurora Cannabis Inc (ACB.TO) went up yesterday by an impressive 24.81%, closing at CA$5.03. This significant gain comes as the company reported a narrower loss in its latest quarterly results, indicating a potential turnaround in its financial performance.
Advertisement
Aurora Cannabis Inc
ACB.TO
ACB.TO
Aurora Cannabis Inc
WealthAwesomeMarket cap
$339.98M
52W high
$9.33
52W low
$3.59
1W change
-3.24%
Beta
1.34
Analyst Price Targets
Based on analyst covering ACB
Wall Street analysts forecast ACB stock price to rise 0.2% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$5.38
+0.2% Upside
Current Price
C$5.37
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ACB's historical volatility
30-Day Vol
72.5%
Annualized
90-Day Vol
54.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.42
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.70 | C$4.44 โ C$7.32 |
| 60 trading days | C$6.05 | C$4.25 โ C$8.62 |
| 90 trading days | C$6.42 | C$4.16 โ C$9.90 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may view Aurora's improved financial metrics and strategic focus on international medical cannabis as a positive sign for future growth.
Stock Price Climbs by 24.81%
Aurora's stock price surge reflects growing investor confidence following a substantial reduction in quarterly losses and a strategic pivot towards international medical cannabis.
Bull case
Aurora is making strides in international markets, especially in medical cannabis, which shows promise for future revenue growth and better profitability.
Bear case
However, there are concerns. Aurora's revenue is declining in the Canadian market, and the ongoing challenges in the consumer cannabis sector raise questions about its long-term viability.
Financial Performance Overview
Advertisement
In its latest quarterly report, Aurora Cannabis revealed a significantly reduced net loss of CA$4 million, a 60% decrease compared to the previous year. While net revenue fell by 9% to CA$67.6 million, the growth in international medical cannabis sales, particularly in Germany, has provided a silver lining.
Market Reaction and Future Outlook
The stock's surge reflects a positive market reaction to Aurora's strategic shift towards international markets, which may help the company regain its footing amid declining sales in the Canadian consumer cannabis sector. Investors are hopeful that this pivot will lead to sustained growth and profitability in the coming quarters.
Challenges Ahead
Despite the recent gains, Aurora faces challenges, including a 25% decline in Canadian medical cannabis revenue due to changes in reimbursement rates. The companyโs consumer cannabis segment continues to contract, which could pose risks to its overall recovery strategy.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
